Actinium Pharmaceuticals Appoints Matt David as Chief Financial Officer
Actinium Pharmaceuticals, Inc. (ATNM) has appointed Matt David, M.D., as Chief Financial Officer and principal financial officer. Dr. David will oversee the biopharmaceutical company's financial operations, accounting, capital markets, and investor relations strategy.
Dr. David brings more than 20 years of experience across corporate management, healthcare investment banking, and equity research. He joins from CorMedix Inc. (CRMD), where he served as Chief Business Officer and previously as Chief Financial Officer. During his tenure at CorMedix, the company earned FDA approval for its lead therapy, launched it commercially, and executed a strategic acquisition. He also previously served as head of strategy at Ovid Therapeutics Inc. (OVID) and worked in healthcare finance at several Wall Street firms.
The executive transition comes as Actinium advances its pipeline of targeted cancer radiotherapies. Key programs include ATNM-400, currently undergoing a Phase 1 study in prostate cancer, and Actimab-A, which is moving toward Phase 2/3 development in acute myeloid leukemia. Investors will be tracking how Dr. David's experience guiding growth-stage biopharmaceutical companies supports Actinium's financial strategy and clinical execution.
Key points
- Actinium Pharmaceuticals appointed Dr. Matt David as Chief Financial Officer and principal financial officer.
- Dr. David previously served as Chief Business Officer and Chief Financial Officer at CorMedix.
- His background includes over 20 years in biopharmaceutical leadership, healthcare investment banking, and equity research.
- Actinium is advancing clinical radiotherapy programs, including ATNM-400 and Actimab-A.
Written by our AI from expert market sources across the web. It can contain mistakes: check the facts before acting on them. Write-ups powered by the free AI API at FreeTheAI.org
How we writeDisclaimerQuestions and answers
Who is the new Chief Financial Officer of Actinium Pharmaceuticals?
Dr. Matt David has been appointed as Chief Financial Officer and principal financial officer of Actinium Pharmaceuticals.
What background does Matt David have before joining Actinium?
Dr. David previously served as CBO and CFO at CorMedix, head of strategy at Ovid Therapeutics, and worked in healthcare investment banking and equity research.
What clinical programs is Actinium Pharmaceuticals currently advancing?
Actinium is developing targeted radiotherapies, including ATNM-400 in Phase 1 trials and Actimab-A moving toward Phase 2/3 clinical studies.